Tag: reimbursement-risk
Boston Scientific Stock Analysis: Valuation, Reimbursement Risk, Cash Flow & Growth
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can sustain execution while navigating reimbursement pressure and acquisition-led capital deployment.